ascorbic-acid and 6-deoxy-6-bromoascorbic-acid

Vitamin C intracellular accumulation is mediated by Na(+)-dependent vitamin C transporters SVCT1 and -2 and dehydroascorbic acid transporters GLUT1 and -3. It is unclear which pathways dominate in vivo. As a new step to resolve this issue, we identified and tested 6-bromo-6-deoxy-L-ascorbic acid as a specific candidate for SVCTs. In high performance liquid chromatography and electron paramagnetic resonance analyses, the reduced compounds ascorbic acid and 6-bromo-6-deoxy-L-ascorbic acid were similar. The oxidized products 6-bromo-6-deoxy dehydroascorbic acid (BrDHA) and dehydroascorbic acid (DHA) had comparable stabilities, based on reduction recoveries. Upon expression of GLUT1 or GLUT3 in Xenopus oocytes, BrDHA was neither transported nor bound, in contrast to robust transport of DHA. The findings were not explained by differences in the oocyte reduction of DHA and BrDHA because lysed oocytes reduced both compounds equally. Further, there was no transport of the reduced compound, 6-bromo-6-deoxy-L-ascorbic acid, by GLUT1 or GLUT3. As a prerequisite for investigating 6-bromo-6-deoxy-L-ascorbic acid transported by SVCTs, SVCT2 transport activity in oocytes was enhanced 14-fold by construction and use of a vector that added a fixed poly(A) tail to the 3' end of cRNA. For SVCT1 and SVCT2 expressed in oocytes, similar K(m) and V(max) values were observed for ascorbic acid and 6-bromo-6-deoxy-L-ascorbic acid. In human fibroblasts, predicted to have SVCT-mediated ascorbate accumulation, K(m) and V(max) values were again comparable for ascorbic acid and 6-bromo-6-deoxy-L-ascorbic acid. Using activated human neutrophils, predicted to have ascorbate accumulation mediated predominantly by DHA and GLUT transporters, 6-bromo-6-deoxy-L-ascorbic acid accumulation was <1% of accumulation when compared with ascorbic acid. We conclude that 6-bromo-6-deoxy-L-ascorbic acid is the first transport substrate identified as completely specific for SVCTs, but not GLUTs, and provide a new strategy to determine the contribution of each pathway to ascorbate accumulation.

Topics: Animals; Ascorbic Acid; Biological Transport; Chromatography, High Pressure Liquid; Electron Spin Resonance Spectroscopy; Fibroblasts; Glucose; Humans; Kinetics; Monosaccharide Transport Proteins; Neutrophils; Oocytes; Organic Anion Transporters, Sodium-Dependent; Oxidation-Reduction; Poly A; Rats; RNA, Messenger; Sodium; Sodium-Coupled Vitamin C Transporters; Symporters; Xenopus laevis

Ascorbic acid (AA) or 6-Br-ascorbate (BrAA) conjugation has been investigated as a tool to improve brain drug delivery by the Vitamin C transporter SVCT2. To this aim, the effects of AA- or BrAA-conjugation on drug affinity and uptake have been assessed in vitro, by using human retinal pigment epithelium (HRPE) cells, and compared in vivo on mice. Nipecotic, kynurenic and diclofenamic acids were chosen as model drugs. Kinetic and inhibition experiments referred to [(14)C]AA uptake into HRPE cells showed that nipecotic and kynurenic acids became able to interact with SVCT2, as competitive inhibitors, only when conjugated to AA or BrAA. Surprisingly, diclofenamic acid itself appeared able to interact with SVCT2, with an affinity that was significantly increased or decreased by AA or BrAA conjugation, respectively. HPLC analysis, performed on HRPE cells, confirmed the SVCT2 mediated transport for the BrAA-conjugate of nipecotic acid, whereas kynurenic acids conjugates although interacting with the transporter did not enter the cells. In accordance, only the nipecotic acid conjugates showed anticonvulsant activity after systemic injection in mice.

Topics: Animals; Ascorbic Acid; Cell Line; Central Nervous System Agents; Dose-Response Relationship, Drug; Drug Synergism; Male; Mice; Seizures; Structure-Activity Relationship

Preliminary investigations allowed us to anticipate that conjugation of nipecotic acid with L-ascorbate (AA) gave a prodrug endowed with anticonvulsant activity in mice. In view of these results, and in order to get deepen insight into the molecular aspects at the base of the transport mechanism, a second generation of compounds, based on 6-bromo-6-deoxy-L-ascorbic acid (BrAA) as the carrier molecule was designed and synthesized. Effects of the chirality of the transported drug was also investigated on R- and S-nipecotic acid. Interaction and uptake modalities were evaluated in our in vitro model based on human retinal pigment epithelium cells (HRPE), which expresses the membrane L-ascorbic acid (AA) SVCT2 transporters. A remarkable increase on SVCT2 affinity was found going from AA to BrAA conjugates, that is, 11 (Ki=1187+/-78 microM) versus 19 (Ki=193+/-14 microM) and 12 (Ki=39.8+/-3.2 microM) versus 20, (Ki=7.4+/-0.8 microM). Taken together, these data are in agreement with our initial hypothesis on the possibility to achieve better affinities by conjugation with AA analogs, and also consent to hypothesize the presence of accessory interactions that may improve transporters recognition.

Topics: Animals; Ascorbic Acid; Central Nervous System Agents; Humans; Kynurenic Acid; Mice; Nipecotic Acids; Organic Anion Transporters, Sodium-Dependent; Pigment Epithelium of Eye; Prodrugs; Sodium-Coupled Vitamin C Transporters; Symporters

The results of the present study demonstrate that 6-bromo-6-deoxy-L-ascorbic acid (6-BrAA), an antioxidative derivative of ascorbic acid, is capable of lowering the toxicity of cisplatin, cis-diaminedichloroplatinum (cis-DDP), an anticancerogenic drug. The biological aspects and pharmacological significance of a combined treatment of these two substances were investigated in a mouse model. The results indicate that the effectiveness of 6-BrAA on biological response(s) is strongly dependent on the dose of cis-DDP. Injection of 10 mg/kg body weight (bw) of cis-DDP following pretreatment with 6-BrAA (480 mg/kg bw) enhances the tissue-protecting effect of 6-BrAA and reduces, to some extent, the ensuing nephro-, liver and spleen toxicity. On the other hand, 6-BrAA in animals treated with a higher dose of cis-DDP (15 mg/kg bw) leads to exacerbation of the toxic cis-DDP effect and concurrent loss of the protective potential of 6-BrAA with respect to tissue damage. The exact mechanism(s) of 6-BrAA protection and exacerbation of the toxic cis-DDP effect is unclear, although scavenging or generating of free radicals may play an important role. The results obtained may be of importance in planning the rational use of cis-DDP and 6-BrAA administration in the potential treatment of cancer.

Topics: Acid Phosphatase; Animals; Antineoplastic Agents; Ascorbic Acid; Blood Urea Nitrogen; Cisplatin; Dose-Response Relationship, Drug; Female; Lipid Peroxidation; Liver; Mice; Mice, Inbred CBA; N-Acetylneuraminic Acid; Thiobarbituric Acid Reactive Substances; Time Factors

The antiscorbutic activity of 6-bromo-6-deoxy-L-ascorbic acid (I) in guinea pigs was compared to that of ascorbic acid (AsA). The growth test results in guinea pigs did not show any significant difference between the body weight increase in the respective 2 groups given compound (I) and that in the group given AsA. Scorbutic guinea pigs were found to completely recover from the disease after administration of the compound (I). There were no significant differences in the plasma alkaline phosphatase activity and the hydroxyproline content in the tibia between the group given compound (I) and that given AsA. The total vitamin C contents in the various tissues were similar in the 2 groups given compound (I) and the C-deficient group but they were lower than the levels for the group given AsA. It was shown that antiscorbutic activity was characteristic of compound (I) and it was almost equal to the effect of AsA.

Topics: Alkaline Phosphatase; Animals; Ascorbic Acid; Body Weight; Brain Chemistry; Guinea Pigs; Hydroxyproline; Kidney; Liver; Male; Scurvy; Spleen; Tibia

6-Bromo- and 6-chloro-6-deoxy derivatives of ascorbate anion are able to transfer an electron to the oxidizing radicals .OH, Br2.- and RS. with the same rate constants as the ascorbate anion itself. The resulting radicals also show the same kinetic stabilities and optical absorption spectra as the well-characterized ascorbate radical anion (lambda max = 360 nm; epsilon 360 = 330 m2 mol-1). This proves that there is no influence of the structural changes in the side chain on the antioxidant capacity of the ascorbate moiety. In contrast, measured reduction of the 6-halo-6-deoxy derivatives occurs significantly faster (up to one order of magnitude) than the reduction of unsubstituted ascorbate. For example, absolute rate constants of 4.6 x 10(9) and 2.2 x 10(7) dm3 mol-1 s-1 have been measured for the reactions of bromo-derivative with eaq- and (CH3)2COH respectively. These radical-induced reductions proceed via dissociative electron capture and, under cleavage of the C-halogen bond, yield C-6 carbon-centered radicals. In the presence of oxygen the corresponding peroxyl radical is readily formed. This radical is again able to oxidize the ascorbate moiety (rate constant 2 x 10(7) dm3 mol-1 s-1). Results are discussed in terms of biological relevance of the investigated compounds regarding their ability to act as efficient antioxidants and bioreductive antitumour agents simultaneously.

Topics: Ascorbic Acid; Electrons; Free Radicals; Oxidation-Reduction; Oxygen

The influence of 6-deoxy-6-bromo-ascorbic acid (6-Br-AA) and ascorbic acid (AA) on the growth of mouse melanoma cell line B16, mouse fibroblasts (L929), and human cervical carcinoma HeLa cells was examined by in vitro experiments. 6-Br-AA was added in concentrations 10(-1) to 10(-8)M and for incubation periods of 2, 18, 24 and 72 h. The present results indicate that 6-Br-AA exhibits a highly pronounced inhibiting effect on growth and DNA synthesis of melanoma cells. Inhibitory effect of 6-Br-AA was confirmed by the in vivo experiments. The tumor-suppressing effect on solid melanoma B16 was attained with 9 mg per mouse given three times daily for 16 days. Our preliminary results indicate that 6-Br-AA could serve as a potential antitumor agent.

Topics: Animals; Antineoplastic Agents; Ascorbic Acid; Cell Division; Fibroblasts; HeLa Cells; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL